stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) Return on equity
Legend Biotech Corporation Sponsored ADR's return on equity over the twelve months to 30 June 2026 was −8.08%, up 21.0 percentage points from fiscal 2025 (−29.1%). Over the past ten years it has ranged from −385.7% (fiscal 2020) to 232.8% (fiscal 2019); the current reading is higher than 56% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −29.1% | (13.61) |
| FY2024 | −15.5% | 36.49 |
| FY2023 | −51.9% | 7.17 |
| FY2022 | −59.1% | 18.04 |
| FY2021 | −77.2% | 308.50 |
| FY2020 | −385.7% | (618.48) |
| FY2019 | 232.8% | 259.79 |
| FY2018 | −27.0% | (116.15) |
| FY2017 | 89.2% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | 14.9% |
| LEGN Legend Biotech Corporation Sponsored ADR | −8.08% |
| ABCL AbCellera Biologics Inc. compare | −17.3% |
| TNGX Tango Therapeutics, Inc. compare | −21.3% |
| DNTH Dianthus Therapeutics, Inc. compare | −22.6% |
| IOVA Iovance Biotherapeutics, Inc. compare | −29.1% |
| RLAY Relay Therapeutics, Inc. compare | −36.8% |
| EWTX Edgewise Therapeutics, Inc. compare | −38.0% |
| DFTX Definium Therapeutics, Inc. compare | −64.1% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on LEGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement